Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branislav Jeremić

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 3, 2012
Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patientsBranislav Jeremić, Biljana Miličić, Slobodan Milisavljevic
Clinical Lung Cancer|January 8, 2013
Radiotherapy alone vs. radiochemotherapy in patients with favorable prognosis of clinical stage IIIA non-small-cell lung cancerBranislav Jeremić, Biljana Miličić, Slobodan Milisavljević
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II studyBranislav Jeremić, Biljana Milicić, Ljubisa Acimović, et al.
Current Oncology (Toronto, Ont.)|November 10, 2022
Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer-How to Identify Patients Which Can Benefit from It?Branislav Jeremić, Elene Mariamidze, Inga Shoshiashvili, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|January 4, 2007
Normal tissue complications after radiation therapyJolyon H Hendry, Branislav Jeremić, Eduardo H Zubizarreta
Srpski Arhiv Za Celokupno Lekarstvo|December 3, 2009
[Muscle strength measurement of pelvic floor in women by vaginal dynamometer]Katarina Parezanović-Ilić, Milorad Jevtić, Branislav Jeremić, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2006
Pretreatment prognostic factors in patients with early-stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy aloneBranislav Jeremić, Biljana Milicić, Aleksandar Dagović, et al.
Srpski Arhiv Za Celokupno Lekarstvo|November 11, 2011
[Physical therapy in the treatment of stress urinary incontinence]Katarina Parezanović-Ilić, Branislav Jeremić, Ljiljana Mladenović-Segedi, et al.
Clinical Lung Cancer|December 20, 2015
Surgery for Stage IIIA Non-Small-cell Lung Cancer: Lack of Predictive and Prognostic Factors Identifying Any Subgroup of Patients Benefiting From ItBranislav Jeremić, Francesc Casas, Pavol Dubinsky, et al.
Frontiers in Human Neuroscience|May 6, 2016
Benefits of Instructed Responding in Manual Assembly Tasks: An ERP ApproachPavle Mijović, Vanja Ković, Maarten De Vos, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 3, 2012
Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patientsBranislav Jeremić, Biljana Miličić, Slobodan Milisavljevic
Clinical Lung Cancer|January 8, 2013
Radiotherapy alone vs. radiochemotherapy in patients with favorable prognosis of clinical stage IIIA non-small-cell lung cancerBranislav Jeremić, Biljana Miličić, Slobodan Milisavljević
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II studyBranislav Jeremić, Biljana Milicić, Ljubisa Acimović, et al.
Current Oncology (Toronto, Ont.)|November 10, 2022
Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer-How to Identify Patients Which Can Benefit from It?Branislav Jeremić, Elene Mariamidze, Inga Shoshiashvili, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|January 4, 2007
Normal tissue complications after radiation therapyJolyon H Hendry, Branislav Jeremić, Eduardo H Zubizarreta
Srpski Arhiv Za Celokupno Lekarstvo|December 3, 2009
[Muscle strength measurement of pelvic floor in women by vaginal dynamometer]Katarina Parezanović-Ilić, Milorad Jevtić, Branislav Jeremić, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2006
Pretreatment prognostic factors in patients with early-stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy aloneBranislav Jeremić, Biljana Milicić, Aleksandar Dagović, et al.
Srpski Arhiv Za Celokupno Lekarstvo|November 11, 2011
[Physical therapy in the treatment of stress urinary incontinence]Katarina Parezanović-Ilić, Branislav Jeremić, Ljiljana Mladenović-Segedi, et al.
Clinical Lung Cancer|December 20, 2015
Surgery for Stage IIIA Non-Small-cell Lung Cancer: Lack of Predictive and Prognostic Factors Identifying Any Subgroup of Patients Benefiting From ItBranislav Jeremić, Francesc Casas, Pavol Dubinsky, et al.
Frontiers in Human Neuroscience|May 6, 2016
Benefits of Instructed Responding in Manual Assembly Tasks: An ERP ApproachPavle Mijović, Vanja Ković, Maarten De Vos, et al.
Pageof 3